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proliferate, express KIR and NKG2A receptors and develop cyto-
toxic and cytokine-producing potential. Umbilical cord blood, a
site of developing hematopoiesis, contained a signiﬁcantly higher
percentage of CD56dim NKG2A-KIR- cells (59 	 11%) support-
ing the notion that these cells are developmentally immature. We
conclude that lineage-committed NK cells in the blood do not
require inhibitory self-tolerance mechanisms until they reach a late
stage of differentiation.
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PRE-CLINICAL STUDY OF THE EFFECT OF THE AS-SIG-TAA/ECDCD40L
VECTOR PRIME-TAA/ECDCD40L PROTEIN BOOST VACCINE IN ELDERLY
RECIPIENTS FOR SUPPRESSION OF RECURRENT CANCER FOLLOWING
ALLOGRAFTING AND DONOR LYMPHOCYTE INFUSIONS (DLI)
Tang, Y.1, Akbulut, H.1, Maynard, J.1, Petersen, L.1, Deisseroth, A.1
1Sidney Kimmel Cancer Center, San Diego, CA.
The mini-allogeneic transplant has opened the door to treat-
ing individuals in the ﬁfth and sixth decades of life. Unfortu-
nately, matched related donors for these individuals usually have
an aged immune system in which the immune response has been
impaired by a reduction in the ratio of antigen naı¨ve/memory
CD4 and CD8 T cells and acquired functional defects in acti-
vated “helper” CD4 T cells (eg diminished CD40 ligand
(CD40L) expression). This has limited the applicability of mini-
allografts to older individuals and to the use of post allograft
vaccines to expand speciﬁc populations of CD8 effector cells to
bolster the anti-cancer and anti-viral immune response. Our
laboratory has developed an adenoviral vector (Ad-sig-TAA/
ecdCD40L) vaccine which is designed for the in vivo target
associated antigen (TAA) loading and activation of dendritic
cells (DCs), and to overcome the absence of CD40L expression
in activated CD4 helper T cells in older individuals. The sub-
cutaneous (sc) injection of this vector leads to the release of a
fusion protein composed of a TAA linked to the extracellular
domain (ecd) of the CD40 ligand (CD40L), which binds to the
CD40 receptor on DCs, activates the DCs, and leads to the
presentation of TAA fragments on Class I MHC. VPP vaccine
overcomes anergy in TAA.Tg transgenic mouse, and induces
TAA speciﬁc memory cells. Two sc injections of the TAA/
ecdCD40L protein as a booster following the sc administration
of the Ad-sig-TAA/ecdCD40L vector (VPP) expands the mag-
nitude of the cellular and humoral immune response induced by
the vector in 18 month old aged mice as well as in younger mice.
This vaccine decreased levels of negative regulatory CD4
FOXP3 T cells in tumor nodules. We administered TBI and an
allogeneic stem cell transplant 7 days post sc injection of the E7
positive TC-1 cells. DLI from an Ad-sig-E7/ecdCD40L vector
prime-E7/ecdCD40L protein boost vaccinated donor were in-
jected iv 3 days post transplant, and a single E7/ecdCD40L
protein boost sc vaccination one week thereafter. We found that
the growth rate of the E7 positive TC-1 tumor cells post
allograft was less in the vaccinated than in the control (injection
of tumor cells followed in 7 days by TBI), or the animals in
which the allograft recipient was vaccinated without DLI. Thus,
the use of DLI from VPP vaccinated allodonor decreased tumor
cell growth post allograft.
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DIRECT ISOLATION AND INFUSION OF DONOR-DERIVED CMV-SPECIFIC
T CELLS FOR TREATMENT OR PROPHYLAXIS OF CMV INFECTION
FOLLOWING ALLOGENEIC TRANSPLANTATION
Lowdell, M.W.1, Thomson, K.1, Julie, A.1, Pang, K.1, Samuel, E.1,
Desborough, M.1, Mackinnon, S.1 1Dept of Haematology, Royal Free &
UCL Med Sch, London, United Kingdom.
Reactivation of CMV is common following allogeneic HSCT
and virus-speciﬁc T lymphocytes are necessary for control.
CMV-speciﬁc donor T cell infusions have been used but most
methods involve several weeks of ex-vivo culture. The current
method involves a 20hr incubation of donor peripheral blood
mononuclear cells with rCMV-pp65 protein. Isolation of inter-
feron-gamma positive T cells by CliniMACS using IFN cap-
ture microbeads (Miltenyi Biotec) provides a CMV-reactive T
cell product which is cryopreserved in dosed aliquots for sub-
sequent infusion. A single arm phase I study is underway, with
CMV-T cells given pre-emptively at ﬁrst detection (by qPCR)
of CMV DNA in peripheral blood, or at day 40-50 as pro-
phylaxis. A dose of 1104 CD3/kg recipient weight is infused
and CMV monitored by weekly PCR. Antiviral drug therapy
commences if the viral load rises above our institutional thresh-
old. 12 patients have received CMV-T cells at a median of 4
weeks post HSCT and 9 are alive and well. None experienced
infusion-related toxicity and no deaths were associated with
CMV-T cell treatment or CMV disease. Incidence and severity
of GvHD was no different from historical controls. The median
yield of CMV-T cells following enrichment was 5.2106 (range
0.29-26.7) of which 24.7% were CD4/IFN and 11.2% were
CD8/IFN; a total mean CMV-reactive cell yield of 2.2
106 per donor. Following infusion, in vivo expansion of
CMV-T cells was seen in all patients. CMV-T cells averaged
9.8% of CD4 cells and 8.1% of CD8 cells by 2-4 weeks
post-infusion; the result of in vivo expansions of CMV-reactive
cells of up to 5000-fold. 9 patients received antiviral therapy for
CMV reactivation but in 5 patients this was required for a
signiﬁcantly shorter period than in historical controls (11-14
days). 3 patients had a second CMV reactivation. 1 patient
showed substantially delayed expansion of CMV-T and required
prolonged anti-viral treatment (33 days). 1 required antiviral
drug treatment, the second received no treatment and cleared
virus after a further in vivo expansion of CMV-T cells, suggest-
ing the presence of a functional memory population. 3 patients
were treated prophylactically at day 40-50 and expansions of
CMV-reactive T cells were seen in all 3 despite lack of detect-
able viral DNA in peripheral blood. This technique rapidly
provides clinical-grade CMV-reactive CD4 and CD8 T cells
which appear to provide effective antiviral immunity.
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THYMIC SHIELDING (TS) IN RECIPIENTS OF TOTAL BODY IRRADIA-
TION (TBI) AND ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL
TRANSPLANT (AD-HSCT): REDUCED RISK OF OPPORTUNISTIC INFEC-
TION IN PATIENTS WITH FANCONI ANEMIA (FA)
MacMillan, M.L.1, Blazar, B.R.1, DeFor, T.E.1, Dusenbery, K.R.1,
Wagner, J.E.1 1University of Minnesota, Minneapolis, MN.
Delayed immune reconstitution and consequent opportunistic
infections remain major obstacles to the successful application
of HSCT, particularly in older patients, those with HLA mis-
matched donors and in selected diseases, such as FA. Based on
preclinical work suggesting that TS may improve immune re-
constitution in recipients of TBI and allogeneic HSCT (J Im-
munol 1987:139:358), we evaluated the safety and potential
efﬁcacy of TS in FA patients. After CT localization of the
thymus, 5HVL cerrubend blocks were fabricated and used to
shield the thymus. Otherwise all patients received the standard
preparative regimen consisting of ﬂudarabine 175 mg/m2, cy-
closphosphamide 40 mg/kg, single fraction TBI 450 cGy, and
antithymocyte globulin, with cyclosporine and short course
methylprednisolone as GVHD immunoprophylaxis. In order to
assess the potential risks and beneﬁts of TS, we compared
transplant outcomes of these FA patients who received TS to FA
patients treated with the exact same preparative regimen with-
out TS. Between April 1999-June 2006, 59 FA patients under-
went AD-HSCT at the University of Minnesota; 16 patients had
TBI with TS and 43 had TBI without TS. For those with and
without TS, donors were HLA matched (n42) or mismatched
(n17), and stem cell sources were T cell depleted bone marrow
(n9 vs n38) or umbilical cord blood (n7 vs n5). While
excess graft failure was considered to be the principal toxicity
risk in recipients of TS, incidence of engraftment was similar in
those with and without TS (94% vs 97% respectively, p.46).
Although not statistically signiﬁcant, survival at one year was
higher in FA patients with TS (67% vs 53% respectively,
p.46). However, as shown, TS was associated with a signiﬁ-
cantly lower risk of all three categories of opportunistic infec-
tion after HSCT (Table 1).
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In conclusion, TS in recipients of TBI is associated with signif-
icantly lower risk of opportunistic infections without any deleteri-
ous effect on hematopoietic recovery in recipients of AD-HSCT.
While these results indicate that TS reduces the infection rate and
potentially improves survival in patients with FA, they also suggests
that TS should be considered for other high risk populations (e.g.
adults) and in those with other non malignant disorders. While it
appears that immune reconstitution is improved based on the
reduced incidence of opportunistic infections, correlative labora-
tory assessments (TREC, CD4 recovery) are currently being per-
formed.
Impact of TS on HSCT Outcomes
Preparative
Therapy
Probability
of
Neutrophil
Engraftment
(95% CI)
Probability
of Survival
at 1 Year
(95% CI)
Total #
Infections
#Bacterial
Infections
#Viral
Infections
#Fungal
Infections
TBI with
TS
(n16
patients) 94(82-100) 67(23-91) 9 4 3 2
TBI
Without
TS
(n43
patients) 97(92-100) 53(38-68) 126 68 37 21
P value NS NS <.01 <.01 <.01 <.01
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CD4CD25 REGULATORY T CELLS ENHANCE IMMUNE RECONSTI-
TUTION FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION BY PROTECTING THYMIC AND LYMPHOID COMPART-
MENTS FROM GRAFT-VERSUS-HOST DISEASE DAMAGE WITHOUT
IMPACTING T CELL REPERTOIRE DEVELOPMENT
Nguyen, V.H.1, Chang, D.1, Shashidhar, S.1, Bachmann, M.1,
Contag, C.H.1, Brown, J.M.Y.1, Negrin, R.S.1 1Stanford University
School of Medicine, Stanford, CA.
We previously showed that Treg improved the quantitative
and functional lymphoid reconstitution in a murine model of
bone marrow transplantation. We hypothesize that Treg pre-
vent thymic and lymphoid damage from graft-versus-host dis-
ease (GvHD), leading to enhanced lymphoid reconstitution.
Lethally-irradiated adult thymectomized Balb/c (H2d) recipi-
ents received FVB (H2q) T cell depleted bone marrow (TCD-
BM) cells and CD4/CD8 cells (Tcon), the latter to induce
GvHD, with or without donor Treg. At day 30, when all groups
had reached full donor chimerism, transplant recipients were
challenged with murine CMV (5105 pfu/mouse). Day 90 sur-
vival for thymectomized groups with TCD-BM alone, with
Tcon, or with TconTreg was 78%, 0%, and 45%, respec-
tively, compared to 100%, 0%, and 86% survival in their re-
spective euthymic infected counterparts (p0.05 for thymecto-
mized vs euthymic Treg groups). Elispot showed CMV speciﬁc
donor responses in infected groups. Viral titers in the liver and
kidney 2 weeks after infection was lower in Treg recipients
compared to animals that received Tcon alone. Thymectomized
animals had higher viral titers compared to euthymic controls.
Uninfected thymectomized controls in the respective groups
separate the effect of CMV infection from GvHD on survival.
Treg recipients, infected or uninfected, had no clinical GvHD
compared to animals that received Tcon alone. In euthymic
recipients, gross and histologic examination conﬁrmed the gen-
eral preservation of thymic integrity and architecture in Treg
recipients compared with smaller involuted thymuses partially
replaced by adipose tissue in animals that received Tcon alone.
V-beta TCR screening with FACS showed a polyclonal TCR
repertoire in animals with or without Treg. Spectratyping 30
days post-transplantation showed that Treg had no signiﬁcant
impact on the TCR repertoire diversity in animals which re-
ceived Tcon. Survival of a subset of infected thymectomized
animals that received Treg lead to the evaluation of the impact
of Treg on secondary lymphoid organs following HCT. Animals
without Treg had signiﬁcant splenic and lymph node ﬁbrosis
and hypoplasia with a reduction in T cell numbers due to
GvHD. Our ﬁndings indicate that Treg indirectly enhance
immune reconstitution by protecting the thymic and secondary
lymphoid compartments from GvHD damage, allowing the
generation and peripheral expansion of lymphoid cells without
impacting the diversity of T cell repertoire.
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TRANSPLANT CONDITIONS DETERMINE THE CONTRIBUTION OF HOMEO-
STATICALLY EXPANDED DONOR CD8 CELLS TO HOST LYMPHOID RECON-
STITUTION FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
Roskos, M.1, Levy, R.B.1 1University of Miami, Miami, FL.
Patients undergoing hematopoietic cell transplantation (HCT) typ-
ically experience a period of immune deﬁciency commensurate with
levels of pre-transplant conditioning. Accordingly, developing ap-
proaches to facilitate the reconstitution of the host T cell compart-
ment and restore host immune function post-HCT is an important
clinical challenge. The capacity of T cells to expand under conditions
of lymphopenia is well recognized. To determine the contribution of
homeostatically expanded donor memory CD8 cells (TM) on the
reconstitution of the host CD8 compartment post-HCT, a homoge-
neous TCR-transgenic (tg) TM population was monitored following
transplantation with T cell-depleted C57BL/6 bone marrow into
9.0Gy-conditioned syngeneic recipients. Homeostatic expansion was
assessed by CD8/V5/V2 numbers in recipient spleens begin-
ning 3 days post-HCT. Infused TM expanded for 2 wks then reached
a steady-state splenic number (1.5x1) that was maintained 7
months post-transplant. Similar kinetics and expansion were observed
with a non-tg TM population. To determine how transplant param-
eters affect OT.I homeostatic expansion, reduced intensity condition-
ing, delayed infusion, and varying TM doses were examined. OT.I
TM transplanted after 4.5Gy TBI v 9.0Gy, underwent a shorter
period of expansion (1 v 2 wks) and resulted in lower overall homeo-
static cell numbers (3x2). OT.I TM infused into 9.0Gy-condtioned
recipients a week post-transplant displayed similar kinetics and
reached the same homeostatic number as OT.I cells infused at the
time of transplant. However, when the infusion was delayed for 3 wks,
there was marked reduction in expansion and lower homeostatic
numbers (6x2). Transplantation of 0.1106 OT.I TM v 1.5106
TM, after 9.0Gy, TBI resulted in a shorter period of expansion (1 v 2
wks) and lower set-point (4x2). Interestingly, transplantation of
10106 TM resulted in a rapid expansion the ﬁrst week and steep
contraction the second week followed by a rebound expansion and
contraction. Notably, the ultimate set-point was greater than that
achieved with 1.5106 TM (1.5x1). In total, these results demon-
strate the period of expansion and ultimate homeostataic numbers
depend on the level of conditioning, timing of infusion, and number
of TM transplanted. We conclude these parameters are important
when engineering new strategies designed to enhance immune func-
tion post-transplant, including both immediate anti-tumor immunity
and long-term anti-viral protection.
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HAPLOTYPE MISMATCHED MYELOABLATIVE STEM CELL TRANSPLAN-
TATION: PHASE I CLINICAL TRIAL OF DONOR LYMPHOCYTE INFUSION
DEPLETED OF ALLOREACTIVE T CELLS TO LIMIT INFECTIONS AND
MALIGNANT RELAPSE WITHOUT CAUSING GVHD
Roy, D.C.1, Cohen, S.1, Busque, L.1, Fish, D.1, Kiss, T.1, Lachance, S.1,
Sauvageau, G.1, Caudrelier, P.2, Roy, J.1 1Hopital Maisonneuve-Rose-
mont, Montreal, QC, Canada; 2Celmed BioSciences, Montreal, QC,
Canada.
Patients with very high risk hematologic malignancies who cannot
ﬁnd an HLA-matched related or unrelated donor can beneﬁt from
haplo-mismatched transplantation. The latter is, however, compli-
cated by frequent and severe infectious complications and disease
relapse due to delayed immune reconstitution. We have previously
reported that photodynamic therapy (PDT) could selectively deplete
donor alloreactive populations while preserving lymphocytes for im-
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